Show
Sort by
-
- Journal Article
- A1
- open access
Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma
-
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL) : a single-arm, multinational, multicentre, open-label, phase 2 trial
-
Effect of age on the efficacy and safety of single agent oral selinexor in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) : a post-hoc analysis of the sadal pivotal study
-
Selinexor efficacy and safety are independent of renal function in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) : a post-hoc analysis from the pivotal phase 2b sadal study
-
Implication of inherited genetic variants associated with follicular lymphoma susceptibility in the prognosis of patients treated by immunochemotherapy in PRIMA study
-
Effect of prior therapy on the efficacy and safety of oral Selinexor in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) : a post-hoc analysis of the SADAL study
-
A phase 2b study of selinexor in patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
-
- Journal Article
- A1
- open access
Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia : results of a phase II study
-
Long term follow-up of the PRIMA study : half of patients receiving rituximab maintenance remain progression free at 10 years
-
Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial